<DOC>
	<DOCNO>NCT02201602</DOCNO>
	<brief_summary>Gliclazide great glucose lower efficacy glibenclamide among type 2 diabetes mellitus patient minor haplotype ( K23/A1369 ) KCNJ11/ABCC gene location .</brief_summary>
	<brief_title>Sulphonylurea Receptor Mutation Responsiveness Gliclazide - Pilot Proof Concept , Randomised Cross-over Study</brief_title>
	<detailed_description>Sulphonylurea ( SU ) glucose-lowering agent use widely treat type 2 diabetes mellitus ( T2DM ) . SU promote insulin secretion pancreatic islet beta cell via bind inhibition ATP-sensitive potassium ( KATP ) channel . The KATP channel make two subcomponents , inner Kir6.2 K+ channel ( cod KCNJ11 gene ) outer SU receptor 1 ( SUR1 ) ( cod ABCC8 gene ) . Although SUs mechanistically similar term increase insulin secretion , bind distinct region Kir 6.2 SUR1 exert function . Different type SU ( e.g . tolbutamide , glibenclamide , glipizide , glimepiride gliclazide ) therefore group bind site ( A/B/A+B site ) KATP channel [ 3 ] . Interestingly , KCNJ11 E23K ( rs5219 ) variant show confer susceptibility T2DM ABCC8 S1369A ( rs757110 ) variant find complete linkage disequilibrium i.e . inherit together genetic block ( haplotype ) . A recent vitro molecular study suggest minor haplotype ( K23/A1369 ) KATP channel sensitive inhibition gliclazide ( bind A-site ) glibenclamide ( bind A+B site ) , increase responsiveness gliclazide largely due A1369 allele . Understanding response two SUs may vary presence minor haplotype ( K23/A1369 ) would therefore beneficial customization patient treatment achieve good clinical outcome .</detailed_description>
	<mesh_term>Gliclazide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes Age 2165 HbA1c &gt; 8.0 % two consecutive visit Currently take insulin regime complex basal insulin Not willing perform selfblood glucose monitoring ( SBGM ) Renal impairment i.e . eGFR &lt; 50mls/min Pregnancy unwilling practice adequate contraception Taking medication may affect blood glucose e.g . systemic glucocorticoid .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>sulphonylureas</keyword>
	<keyword>gliclazide</keyword>
	<keyword>glibenclamide</keyword>
</DOC>